It’s time for a new day to dawn on narcolepsy. If you are among those who struggle with excessive daytime sleepiness, consider helping to advance our understanding of narcolepsy with cataplexy by joining the FirstLight Study. Together, we can awaken new possibilities in the treatment of this disorder.
You may be able to participate in the FirstLightStudy if you:
Are 18–70 years of age*
*Potential participants ages 16 and 17 may be eligible in some countries per local regulatory requirements.
Have a diagnosis of narcolepsy with cataplexy
(narcolepsy type 1)
Have 4 or more episodes per week of cataplexy
while not on medication
If you are interestedinparticipating, the study doctor or staff will review additional study criteria with you.
Qualified participants will receive all study-related drugs (active or placebo) and study-related care at no cost. Participants may be reimbursed for travel and expenses.
Narcolepsy with cataplexy can impose a significant burden on daily life. Researchers are working to identify treatment options that may have an impact on individuals with this disorder.
The FirstLight Study is evaluating the safety and efficacy of an investigational study drug that is being studied for narcolepsy with cataplexy. Participants will receive the investigational study drug or a placebo (a substance that looks like the investigational study drug but does not contain any active ingredients) while also completing various study tests and procedures.
Neither participants nor the study staff will know if participants are receiving the investigational study drug or a placebo. Participants will attend about 10 scheduled study visits over the course of 14 to 23 weeks. The study duration will vary based on current narcolepsy medications (to be discontinued prior to beginning the study). At the end of the study, participants may have the option to enroll in a long-term extension study in which all participants will receive the active study drug.
You can play a role in helping researchers find more ways to study and treat narcolepsy with cataplexy by participating in this clinical research study.
Your Participation Matters
Research has shown that certain diseases and drugs may affect people differently based on several factors, including age, sex assigned at birth, race, and ethnic background. For this reason, it is important that people from all backgrounds be involved in medical research.
About the FirstLightStudy
The FirstLight Study is evaluating the safety and efficacy of an investigational study drug that is being studied for narcolepsy with cataplexy. Participants will receive the investigational study drug or a placebo (a substance that looks like the investigational study drug but does not contain any active ingredients) while also completing various study tests and procedures.
Neither participants nor the study staff will know if participants are receiving the investigational study drug or a placebo. Participants will attend about 10 scheduled study visits over the course of 14 to 23 weeks. The study duration will vary based on current narcolepsy medications (to be discontinued prior to beginning the study) and whether participants are enrolled in the long-term extension study.
You can play a role in helping researchers find more ways to study and treat narcolepsy with cataplexy by participating in this clinical research study.
Diversity Matters
Research has shown that certain diseases and drugs may affect people differently based on several factors, including age, sex assigned at birth, race, and ethnic background. For this reason, it is important that people from all backgrounds be involved in medical research.
